Lenvatinib Can Overcome Immune Resistance in Head and Neck Cancer and Achieve Durable Remission

Abstract

Squamous cell carcinoma head and neck is the sixth most common cancer worldwide and.[1] Multimodality therapies have been advocated for locoregional relapse or metastatic disease.[2] Combination therapy with lenvatinib has been considered to overcome resistance and improve the efficacy.[3] In a recent study of lenvatinib and pembrolizumab conducted in heavily pretreated recurrent and metastatic head and neck cancer, the median overall survival OS was 6.2 months, and the median progression-free survival (PFS) was 4.6 months.[4] This combination is currently undergoing study in LEAP-010.[5] Herein, we report a case of heavily pretreated metastatic head and neck cancer in a patient who was treated with a combination of lenvatinib with pembrolizumab. Article published online: 09 March 2023 © 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India